DE69922529T2 - Ribavirin-interferon-alpha-kombinationstherapie zur vernichtung nachweisbarer hcv-rna in chronisch hepatitis c infizierten patienten - Google Patents

Ribavirin-interferon-alpha-kombinationstherapie zur vernichtung nachweisbarer hcv-rna in chronisch hepatitis c infizierten patienten Download PDF

Info

Publication number
DE69922529T2
DE69922529T2 DE69922529T DE69922529T DE69922529T2 DE 69922529 T2 DE69922529 T2 DE 69922529T2 DE 69922529 T DE69922529 T DE 69922529T DE 69922529 T DE69922529 T DE 69922529T DE 69922529 T2 DE69922529 T2 DE 69922529T2
Authority
DE
Germany
Prior art keywords
compound
formula
interferon
effective amount
pharmaceutically acceptable
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE69922529T
Other languages
German (de)
English (en)
Other versions
DE69922529D1 (de
Inventor
K. Ashit GANGULY
Jinping Mccormick
G. Raymond LOVEY
Frank Bennett
K. Anil SAKSENA
M. Viyyoor GIRIJAVALLABHAN
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Merck Sharp and Dohme LLC
Original Assignee
Schering Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US09/348,534 external-priority patent/US6277830B1/en
Application filed by Schering Corp filed Critical Schering Corp
Application granted granted Critical
Publication of DE69922529D1 publication Critical patent/DE69922529D1/de
Publication of DE69922529T2 publication Critical patent/DE69922529T2/de
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07HSUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/056Triazole or tetrazole radicals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/14Antivirals for RNA viruses
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/20Antivirals for DNA viruses
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Virology (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Saccharide Compounds (AREA)
DE69922529T 1998-10-16 1999-10-14 Ribavirin-interferon-alpha-kombinationstherapie zur vernichtung nachweisbarer hcv-rna in chronisch hepatitis c infizierten patienten Expired - Fee Related DE69922529T2 (de)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US174059 1988-03-28
US17405998A 1998-10-16 1998-10-16
US348534 1999-07-07
US09/348,534 US6277830B1 (en) 1998-10-16 1999-07-07 5′-amino acid esters of ribavirin and the use of same to treat hepatitis C with interferon
PCT/US1999/021448 WO2000023454A1 (en) 1998-10-16 1999-10-14 Ribavirin-interferon alfa combination therapy for eradicating detectable hcv-rna in patients having chronic hepatitis c infection

Publications (2)

Publication Number Publication Date
DE69922529D1 DE69922529D1 (de) 2005-01-13
DE69922529T2 true DE69922529T2 (de) 2005-12-15

Family

ID=26869824

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69922529T Expired - Fee Related DE69922529T2 (de) 1998-10-16 1999-10-14 Ribavirin-interferon-alpha-kombinationstherapie zur vernichtung nachweisbarer hcv-rna in chronisch hepatitis c infizierten patienten

Country Status (20)

Country Link
EP (1) EP1121369B1 (https=)
JP (1) JP2002527522A (https=)
CN (1) CN1330658A (https=)
AT (1) ATE284408T1 (https=)
AU (1) AU762395B2 (https=)
BR (1) BR9915546A (https=)
CA (1) CA2346447C (https=)
CZ (1) CZ20011130A3 (https=)
DE (1) DE69922529T2 (https=)
ES (1) ES2229820T3 (https=)
HU (1) HUP0200447A2 (https=)
ID (1) ID29187A (https=)
IL (1) IL142423A0 (https=)
NO (1) NO20011789L (https=)
NZ (1) NZ510811A (https=)
PL (1) PL347268A1 (https=)
RU (1) RU2001113268A (https=)
SK (1) SK4742001A3 (https=)
TR (1) TR200101085T2 (https=)
WO (1) WO2000023454A1 (https=)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6924270B2 (en) 2000-04-20 2005-08-02 Schering Corporation Ribavirin-interferon alfa combination therapy for eradicating detectable HCV-RNA in patients having chronic hepatitis C infection
TWI332507B (en) 2002-11-19 2010-11-01 Hoffmann La Roche Antiviral nucleoside derivatives
WO2004084796A2 (en) * 2003-03-28 2004-10-07 Pharmasset Ltd. Compounds for the treatment of flaviviridae infections
JP2007501806A (ja) * 2003-08-13 2007-02-01 ハワード ジェイ. スミス アンド アソシエイツ ピーティーワイ エルティーディー ウィルス感染を治療する方法
WO2005049065A2 (en) * 2003-11-19 2005-06-02 Rigel Pharmaceuticals, Inc. Synergistic combinations of dihaloacetamide with interferon or ribavirin for treatment hcv infections
JP2008540425A (ja) 2005-05-02 2008-11-20 ライジェル ファーマシューティカルズ, インコーポレイテッド 代謝可能部分を含む複素環式抗ウイルス性化合物およびその使用
WO2009028575A1 (ja) 2007-08-27 2009-03-05 National University Corporation Nagoya University 血液凝固第vii因子プロモーターの活性化剤及びその利用
WO2009028573A1 (ja) 2007-08-27 2009-03-05 National University Corporation Nagoya University 血液凝固障害におけるリバビリンの利用
WO2011151667A1 (en) 2010-06-02 2011-12-08 Adbula Kurkayev Antiviral compositions
US8492386B2 (en) 2011-10-21 2013-07-23 Abbvie Inc. Methods for treating HCV
EP2583677A3 (en) 2011-10-21 2013-07-03 Abbvie Inc. Methods for treating HCV comprising at least two direct acting antiviral agent, ribavirin but not interferon.
US8466159B2 (en) 2011-10-21 2013-06-18 Abbvie Inc. Methods for treating HCV
DE202012012955U1 (de) 2011-10-21 2014-07-14 Abbvie Inc. Eine Kombination aus mindestens zwei direkt wirkenden antiviralen Wirkstoffen (DAAs) für die Verwendung zur Behandlung von HCV
EA201892448A1 (ru) 2016-04-28 2019-06-28 Эмори Юниверсити Алкинсодержащие нуклеотидные и нуклеозидные терапевтические композиции и связанные с ними способы применения
CA3033867A1 (en) 2016-08-17 2018-02-22 Solstice Biologics, Ltd. Polynucleotide constructs
US11597744B2 (en) 2017-06-30 2023-03-07 Sirius Therapeutics, Inc. Chiral phosphoramidite auxiliaries and methods of their use
CN107513055B (zh) * 2017-08-11 2018-06-22 广东昊邦医药健康有限责任公司 一种利巴韦林衍生化合物及其药物组合物
CN117355311A (zh) 2022-05-05 2024-01-05 阿卜杜拉·库尔卡耶夫 用于恢复生物体生理过程和细胞的药物组合物

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1482736A (en) * 1974-03-18 1977-08-10 Icn Pharmaceuticals 1-(beta-d-ribofuranosyl)-1,2,4-triazole acid derivatives
US4544741A (en) * 1982-03-29 1985-10-01 Robins Roland K Azole dinucleotide compounds and methods for their production
US4925930A (en) * 1988-11-02 1990-05-15 Nucleic Acid Research Institute Synthesis and anti-leukemic activity of alkyl-1-(β-D-ribofuranosyl)[1,2,4]triazole-3-carboximidates
GB9307043D0 (en) * 1993-04-05 1993-05-26 Norsk Hydro As Chemical compounds
US6387365B1 (en) * 1995-05-19 2002-05-14 Schering Corporation Combination therapy for chronic hepatitis C infection
WO1998021223A1 (en) * 1996-11-12 1998-05-22 Medivir Ab Nucleosides

Also Published As

Publication number Publication date
TR200101085T2 (tr) 2001-08-21
CA2346447A1 (en) 2000-04-27
SK4742001A3 (en) 2001-11-06
AU762395B2 (en) 2003-06-26
CZ20011130A3 (cs) 2001-08-15
CN1330658A (zh) 2002-01-09
WO2000023454A1 (en) 2000-04-27
NO20011789D0 (no) 2001-04-09
ATE284408T1 (de) 2004-12-15
CA2346447C (en) 2006-01-31
IL142423A0 (en) 2002-03-10
ES2229820T3 (es) 2005-04-16
BR9915546A (pt) 2001-08-14
DE69922529D1 (de) 2005-01-13
HUP0200447A2 (en) 2002-06-29
ID29187A (id) 2001-08-09
EP1121369B1 (en) 2004-12-08
AU1197500A (en) 2000-05-08
JP2002527522A (ja) 2002-08-27
PL347268A1 (en) 2002-03-25
NZ510811A (en) 2003-06-30
EP1121369A1 (en) 2001-08-08
RU2001113268A (ru) 2003-09-27
NO20011789L (no) 2001-06-11

Similar Documents

Publication Publication Date Title
DE69922529T2 (de) Ribavirin-interferon-alpha-kombinationstherapie zur vernichtung nachweisbarer hcv-rna in chronisch hepatitis c infizierten patienten
US6403564B1 (en) Ribavirin-interferon alfa combination therapy for eradicating detectable HCV-RNA in patients having chronic hepatitis C infection
DE60131250T2 (de) Nucleosid-analoga mit monozyklischen basischen carboxamidingruppen
DE60307503T2 (de) Antivirale nukleosidderivate
US6924270B2 (en) Ribavirin-interferon alfa combination therapy for eradicating detectable HCV-RNA in patients having chronic hepatitis C infection
DE69318031T2 (de) Ematiomerenreine beta-d-dioxolane nucleoside mit selektiver antihepatitis b-virus wirkung
DE60217465T2 (de) Nukleosidderivate als inhibitoren von rna-abhängiger rna viralpolymerase
DE69413529T2 (de) Antivirale verbindungen
DE69721339T2 (de) Monozyklische l-nukleoside, analoga und ihre anwendungen
EP1121370A1 (en) Ribavirin-interferon alfa combination therapy for eradicating detectable hcv-rna in patients having chronic hepatitis c infection
DE69425574T2 (de) L-2',3'-dideoxy-nukleosidanaloga als anti-hepatitis b-(hbv) und anti-hiv-wirkstoffe
DE69633628T2 (de) Dihydropyran-derivate als inhibitoren viraler neuramidase
US6525033B1 (en) Nucleosides with anti-hepatitis B virus activity
US6673775B2 (en) Ribavirin-interferon alfa combination therapy for eradicating detectable HCV-RNA in patients having chronic hepatitis C infection
EP0636372A1 (en) Antiviral, antitumor, antimetastatic, immune system enhancing 7-thia-guanosine derivatives
EP0409227A2 (de) Pyrimidinnucleoside, ihre Herstellung und pharmazeutische Mittel
US6518253B1 (en) Treatment of viral infections using the L-isomer of ribavirin
HK1014663B (en) Enantiomerically pure beta-d-dioxolane nucleosides with selective anti-hepatitis b virus activity

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8339 Ceased/non-payment of the annual fee